Short-term effect of latanoprostene bunod monotherapy on reducing intraocular pressure and altering macular microvasculature Latanoprostene bunod monotherapy on glaucoma

Aim: In this study, we aimed to evaluate the effect of topical latanoprostene bunod (LBN) 0.024% on early intraocular pressure (IOP) and macular microvasculature. Material and Methods: This retrospective study included 46 eyes of 46 treatmentnaive participants with primary open-angle glaucoma disease (POAG) who were initiated on topical LBN 0.024%. IOP values of the patients were compared before and the first month after treatment. Macular and ganglion cell complex thicknesses were evaluated using optical coherence tomography (OCT), and macular vessel density parameters were evaluated using OCT angiography (OCTA). Pre-and post-treatment findings were compared with the paired-sample t-test. Results: At the time of the first presentation, the mean IOP value of the patients was 26.20 +/- 2.84 mmHg. After administration of LBN 0.024%, the mean follow-up IOP value decreased to 14.93 +/- 2.25 mmHg in the first month (p=0.00). When OCTA images taken before and the first month after treatment were compared, it was determined that the early treatment diabetic retinopathy study (ETDRS) value for the outer nasal section significantly increased (p=0.042). There was no significant difference in the remaining parameters showing macular vessel density. Discussion: LBN 0.024% is a topical ocular hypotensive agent effective in lowering IOP in the early period in patients with POAG.